Barclays analyst Luke Sergott raised the firm’s price target on Agilent (A) to $145 from $125 and keeps an Equal Weight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent announces insight series alarm resolution systems for airport security
- Agilent’s Balanced Outlook: Hold Rating Amid Growth Prospects and Valuation Concerns
- Agilent price target raised to $130 from $128 at BofA
- Agilent pharmDx receives EU class C companion diagnostic certification
- Agilent Technologies Surpasses Expectations in Q3 Earnings Call